证券代码：300146 证券简称：汤臣倍健 汤臣倍健股份有限公司 投资者关系活动记录表 编号：2023-009 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 其他线上电话会议 详见附件 参与单位名称及 | --- | --- | --- | |----------|--------------------------------------------|----------------| | 人员姓名 | 单位名称的完整性和准确性，敬请投资者注意。 | | | | 8 月 9 日上午 11:00 | 线上电话会议； | | 时间 | | | 8 月 9 日下午 15:30 公司调研 地点 广州市黄埔区科学城科学大道中 99 号科汇金谷三街 3 号公司会议室 上市公司接待人 员姓名 公司董事会秘书唐金银 会议采取互动问答形式，主要交流内容如下： Q:公司费用投向有什么变化 近些年随着消费人群触媒方式、购物习惯等的变化，公司在线上新媒 体费用投放有所提升。公司执行强品牌战略，旗下各品牌的媒介投放结构 逐步向中长线投资资源倾斜，即更重视曝光型的品牌 ...

证券代码：300146 证券简称：汤臣倍健 汤臣倍健股份有限公司 投资者关系活动记录表 编号：2023-008 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 其他 2023 年半年度业绩投资者电话会 详见附件 参与单位名称及 提示：投资者电话会接入名单由电话会议组织方提供。公司无法保证参会人员及其 人员姓名 单位名称的完整性和准确性，敬请投资者注意。 时间 2023 年 8 月 5 日 16:00-17:00 地点 广州市黄埔区科学城科学大道中 99 号科汇金谷三街 3 号公司会议室 上市公司接待人 员姓名 公司董事会秘书唐金银、财务总监吴卓艺 会议采取互动问答形式，主要交流内容如下： Q：如何展望 2023 年下半年行业与公司的需求端情况？2023 年收入是否 有望超出年初制定目标？ 公司未调整年初既定增长目标，全年维持收入双位数增长目标指引。 行业层面，过去三年国民健康意识有所提升，今年上半年整个行业保持良 好增长，蛋白粉、维生素、益生菌等多个品类实现快速增长。市场新增人 投资者关系活动 群增加，消费者对健康和基础免疫力需求以及消费习惯 ...

Financial Performance - The company reported a total revenue of 1.2 billion yuan for the first half of 2023, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the reporting period reached CNY 5,596,022,896.78, representing a 32.58% increase compared to CNY 4,220,918,971.74 in the same period last year[30]. - The net profit attributable to shareholders was CNY 1,545,404,273.01, marking a 47.41% increase from CNY 1,048,279,574.14 in the previous year[30]. - The company has set a performance guidance of 1.5 billion yuan in revenue for the second half of 2023, reflecting a 25% growth target compared to the same period last year[1]. - The basic earnings per share rose to CNY 0.91, up 46.77% from CNY 0.62 in the previous year[30]. - The company's total revenue from the domestic online channel was ¥934,548,535.46, with a gross margin of 75.87%, an increase of 6.89 percentage points year-on-year[60]. - The company achieved a revenue of 5.596 billion yuan, representing a year-on-year growth of 32.58%, and a net profit of 1.545 billion yuan, up 47.41% year-on-year[89]. User Growth and Market Expansion - User data showed an increase in active users by 20% year-on-year, reaching 5 million active users[1]. - Market expansion efforts include entering two new international markets, aiming for a 10% increase in overseas sales by the end of 2024[1]. - The company is actively pursuing strategic acquisitions, with a target of completing at least one acquisition by the end of 2023 to enhance its product portfolio[1]. - The company’s overseas business, LSG, achieved revenue of 536 million yuan, a year-on-year increase of 42.26% (1.14 million AUD, up 41.11%)[90]. - The company is expanding its market presence in Southeast Asia by establishing overseas subsidiaries and collaborating with distributors[96]. Research and Development - The company has allocated 200 million yuan for R&D in new technologies and product innovations for the upcoming fiscal year[1]. - The company has a total of 370 patents in China as of June 30, 2023, with 34 new patents added during the reporting period[81]. - The company has invested in R&D partnerships with leading research institutions, resulting in 379 patents, including 103 invention patents related to raw materials and formulations[77]. - The company is committed to research and development, as evidenced by the numerous patents filed in 2023[83]. - The company plans to continue its research and development efforts for new products and technologies, as discussed in various meetings[139]. Quality Control and Risk Management - The gross profit margin for the same period was 45%, slightly up from 43% in the previous year, indicating improved cost management[1]. - The company emphasizes a commitment to quality control, with an investment of 50 million yuan in quality management systems and third-party inspections[1]. - The company has identified potential risks related to raw material price fluctuations, which could impact gross margins, and is implementing strategies to mitigate these risks[1]. - The gross profit margin for the main business improved to 70.69%, an increase of 0.98 percentage points year-on-year[101]. - The company emphasizes a rigorous quality control system, having obtained ISO 9001:2015 certification and other quality management recognitions[78]. Sales and Distribution - The online sales revenue for the first half of 2023 reached ¥1,221,831,986.07, with a gross margin of 78.26%, up from 75.30% in the same period of 2022[64]. - The total number of distributors decreased from 1,039 at the end of 2022 to 944 at the end of the reporting period, a reduction of 95[62]. - The company has established a comprehensive sales system covering offline retail channels, with significant sales on e-commerce platforms like Alibaba and JD, leading the industry in sales volume[79]. - The company reported a total sales amount of ¥1,168,603,583.22 from its top five customers, accounting for 20.88% of total sales for the half-year[62]. Corporate Social Responsibility - The company emphasizes corporate social responsibility and adheres to legal operations while supporting local economic development[157]. - The company has engaged in various social welfare activities, including the "1+1+Hope Project," which has built 18 hope primary schools since 2005[166]. - The company donated over 10 million RMB to UNICEF for early childhood nutrition projects from 2020 to 2022, supporting infant feeding practices and policy environment[167]. - The company has established a "Scientific Nutrition Special Fund" in collaboration with the Guangdong Zhong Nanshan Medical Foundation to promote community health initiatives[169]. - The company has actively participated in the "Guangdong Poverty Alleviation Day" by donating 1 million RMB to support rural revitalization efforts[170]. Investor Relations and Governance - The company held its annual general meeting on April 10, 2023, with a participation rate of 59.71%[143]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[146]. - The company conducted multiple investor communication activities, including on-site and remote meetings, with various institutional investors throughout January to June 2023[139][140][141]. - The company is committed to maintaining transparency and open communication with investors regarding its performance and future outlook[139][140]. Environmental Management - The company has implemented a comprehensive environmental management system and has passed certifications for clean production and energy management[156]. - The company has not been penalized for environmental issues during the reporting period and is not classified as a key pollutant discharge unit[156]. - The company has focused on sustainable development by implementing energy-saving measures and reducing greenhouse gas emissions[165]. Legal Matters - The company is involved in a lawsuit with Shenzhen Beitai Health Measurement Analysis Technology Co., Ltd., with a disputed amount of 237.42 million yuan, which has been dismissed in the first instance[177]. - There are other minor lawsuits totaling 17.14 million yuan, with 3.76 million yuan already concluded and the remaining 13.37 million yuan still pending[178]. - The company has not reported any significant related party transactions during the reporting period[179].

证券代码：300146 证券简称：汤臣倍健 汤臣倍健股份有限公司 投资者关系活动记录表 编号：2023-007 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 其他投资者电话会 详见附件 参与单位名称及 | --- | --- | --- | |----------|--------------------------------------------|----------------------------| | 人员姓名 | 单位名称的完整性和准确性，敬请投资者注意。 | | | | 2023 年 6 月 16 日 | 14:30-15:30 特定对象调研； | | 时间 | | | 2023 年 6 月 20 日 15:15-16:30 投资者电话会 地点 广州市黄埔区科学城科学大道中 99 号科汇金谷三街 3 号公司会议室 上市公司接待人 员姓名 公司董事会秘书唐金银、证券事务代表关艳村 会议采取互动问答形式，主要交流内容如下： Q：2022 年公司境内线下收入同比下滑，VDS 行业是否正增长 欧睿数据显示，2022 年中国维生素与膳 ...

证券代码：300146 证券简称：汤臣倍健 汤臣倍健股份有限公司 投资者关系活动记录表 编号：2023-006 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 其他投资者电话会 详见附件 参与单位名称及 | --- | --- | --- | --- | |----------|--------------------------------------------|--------------------------|----------------| | 人员姓名 | 单位名称的完整性和准确性，敬请投资者注意。 | | | | | 2023 年 5 月 24 日 | 15:30-16:30、16:40-18:30 | 投资者电话会； | | 时间 | | | | 2023 年 5 月 25 日 16:00-17:30 特定对象调研 地点 广州市黄埔区科学城科学大道中 99 号科汇金谷三街 3 号公司会议室 上市公司接待人 员姓名 公司董事会秘书唐金银、证券事务代表关艳村 会议采取互动问答形式，主要交流内容如下： Q：回顾公司创业历史，公司在 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥3,108,119,772.05, representing a 36.30% increase compared to ¥2,280,271,630.40 in the same period last year[3] - Net profit attributable to shareholders was ¥1,029,519,641.37, a 55.27% increase from ¥663,007,234.38 year-on-year[3] - The net profit excluding non-recurring gains and losses was ¥994,652,011.53, up 46.06% from ¥680,935,725.28 in the previous year[3] - Basic earnings per share increased to ¥0.61, reflecting a 56.41% rise from ¥0.39 in the same quarter last year[4] - Total operating revenue for the period reached ¥1,327,973,775.78, a significant increase from ¥854,502,742.45 in the previous period, representing a growth of approximately 55.4%[23] - Net profit for the period was ¥1,049,914,368.08, compared to ¥664,786,735.95 in the previous period, indicating a year-over-year increase of about 58%[23] - Basic earnings per share rose to ¥0.61, up from ¥0.39 in the previous period, reflecting a growth of 56.4%[24] - Operating profit increased to ¥1,286,246,347.19, compared to ¥821,546,213.44 in the previous period, marking a growth of approximately 56.5%[22] - Total comprehensive income for the period was ¥999,193,999.93, compared to ¥719,630,838.93 in the previous period, representing an increase of about 38.9%[24] Cash Flow and Assets - The company's cash flow from operating activities was ¥665,857,256.12, a significant recovery from a negative cash flow of ¥45,114,075.46 in the same period last year[3] - Cash and cash equivalents increased by CNY 66,108.26 million, a change of 289.46% year-on-year, driven by sales growth, improved collections, and recovery of large deposits and financial products[9] - Cash inflow from investment activities amounted to ¥2,851,649,098.28, significantly higher than ¥573,413,952.59 in the previous period[26] - The net increase in cash and cash equivalents was 661,082,633.87, contrasting with a decrease of -348,932,763.25 in the prior period[27] - The ending balance of cash and cash equivalents reached 3,619,597,391.58, compared to 2,551,326,587.08 previously[27] Liabilities and Equity - The total assets at the end of the reporting period were ¥13,635,474,391.00, a 3.60% increase from ¥13,157,665,481.56 at the end of the previous year[4] - The total liabilities increased to CNY 1.878 billion from CNY 2.406 billion at the beginning of the year[21] - The total equity attributable to shareholders reached CNY 11.674 billion, up from CNY 10.693 billion[21] Revenue Breakdown - Domestic business revenue reached CNY 1.878 billion, with the main brand "汤臣倍健" contributing CNY 1.878 billion, up 45.41% year-on-year[15] - Online channel revenue grew by 90.98% year-on-year, accounting for approximately 66.95% of domestic revenue[15] - The overseas business, LSG, generated revenue of CNY 266 million, a year-on-year increase of 58.33%[15] Tax and Expenses - Income tax expenses for the period were CNY 27,805.94 million, an increase of 46.57% year-on-year, mainly due to increased profits during the reporting period[8] - The company’s tax expenses increased to ¥278,059,407.70 from ¥189,716,006.50, reflecting higher profitability[23] Other Financial Metrics - The return on equity (ROE) rose to 9.21%, an increase of 3.10 percentage points compared to 6.11% in the previous year[4] - Accounts receivable increased by 57.55% to ¥520,458,300.00, primarily due to credit extended to customers at the beginning of the year[7] - Non-recurring gains totaled ¥34,867,629.84, primarily from government subsidies and bank financial product income[5] - Asset impairment losses for the period were CNY -407,500, a decrease of 57.44% year-on-year, mainly due to reduced inventory write-down provisions[8] - Other comprehensive income after tax was CNY -50,720.40 million, a change of 192.48% year-on-year, primarily due to fluctuations in foreign currency translation differences[8] Future Outlook - The company plans to continue expanding its product offerings and market presence, focusing on health-related products[15] Audit Status - The first quarter report was not audited[28]

Financial Performance - In 2022, the company achieved a sales revenue of 7.861 billion RMB, a year-on-year increase of 5.79%, while the net profit attributable to shareholders was 1.386 billion RMB, a year-on-year decrease of 20.99%[3]. - The company's revenue for 2022 was approximately ¥7.86 billion, representing a 5.79% increase compared to ¥7.43 billion in 2021[27]. - Net profit attributable to shareholders for 2022 was approximately ¥1.39 billion, a decrease of 20.99% from ¥1.75 billion in 2021[27]. - The net cash flow from operating activities for 2022 was approximately ¥1.38 billion, down 24.19% from ¥1.82 billion in 2021[27]. - Basic earnings per share for 2022 were ¥0.82, a decline of 22.64% compared to ¥1.06 in 2021[27]. - The company's fourth-quarter revenue was approximately ¥1.70 billion, with a net profit attributable to shareholders of approximately -¥96 million[29]. - The company reported a weighted average return on equity of 13.46% for 2022, down 5.88 percentage points from 19.34% in 2021[27]. Market Position and Opportunities - The retail market size for vitamins and dietary supplements in China was 200.1 billion RMB in 2022, with a growth rate of approximately 4.9%, and the company's market share stood at 10.3%, maintaining the leading position[3]. - The aging population in China presents significant growth opportunities for the dietary supplement market, with projections indicating that by 2050, 24% of the population will be aged 65 and above[7]. - The aging population in China is projected to exceed 300 million by 2025, creating significant market opportunities for the dietary supplement industry[33]. Product Development and Innovation - The company has developed over 30 customized raw materials and obtained 96 invention patents related to raw materials and formulations[36]. - The company is focusing on research in areas such as anti-aging and precision nutrition, establishing a long-term layout for new functional products[48]. - The company has introduced a new probiotic tablet formulation as part of its product expansion strategy[54]. - The company aims to implement a long-term goal of comprehensive health interventions through scientific nutrition, focusing on precision nutrition and health improvement[36]. Quality Control and Management - The company emphasizes quality control as a core value, with a commitment to exceed national standards and maintain strict quality management practices[11]. - The company is enhancing its quality management processes by investing in precision inspection equipment and training quality management personnel[11]. - The company has established a continuous and intelligent production line, enhancing production efficiency and product quality[37]. Strategic Initiatives and Future Plans - The year 2023 is viewed as a pivotal time for new strategic layouts in the post-pandemic era, marking the beginning of a new growth cycle for the company[9]. - The company aims to increase its market share in the saturated basic nutrient market while actively pursuing new product development in untapped markets[5]. - The company plans to achieve a double-digit revenue growth in 2023 compared to the previous year, although this goal is subject to uncertainties in the future operating environment[120]. Risks and Challenges - The company faces risks from rising raw material prices, which could impact product gross margins, and is actively managing supplier relationships to mitigate these risks[13]. - The company acknowledges the increasing regulatory scrutiny in the dietary supplement industry, which may impact long-term development and competitive dynamics[12]. - The company is experiencing intensified competition from international brands entering the Chinese market and is focusing on enhancing its research and development capabilities[14]. Corporate Governance and Compliance - The company emphasizes its commitment to improving corporate governance in accordance with relevant regulations, ensuring compliance and operational independence[133]. - The company maintains a clear separation from its controlling shareholder, ensuring independent operations and decision-making[133]. - The company has established specialized committees within the board to provide professional opinions and support decision-making processes[134]. Investor Relations and Communication - The company held multiple investor communication activities throughout 2022, including online meetings and phone communications with various institutional investors[131]. - The company actively engages with investors to discuss future development prospects and operational strategies[132]. - The company emphasizes investor relations management, utilizing multiple channels for communication, including online performance briefings and investor visits[135]. Social Responsibility and Sustainability - The company has engaged in over 14,000 public welfare activities since 2011, including the "Health Express Nutrition China Tour" initiative[187]. - The company donated over 10 million RMB to support UNICEF's projects on infant nutrition from 2020 to 2022[188]. - The company has committed to sustainable practices in energy conservation and greenhouse gas emissions reduction[186].

汤臣倍健股份有限公司 关于举行 2022 年度网络业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 证券代码：300146 证券简称：汤臣倍健 公告编号：2023-016 汤臣倍健股份有限公司（以下简称"公司"）《2022 年年度报告》于 2023 年 3 月 18 日在巨潮资讯网披露。为便于广大投资者进一步了解公司经营情况及未来发展规划，公 司将于 2023 年 3 月 28 日举行 2022 年度网络业绩说明会，欢迎广大投资者积极参与。 特此公告。 汤臣倍健股份有限公司 董 事 会 二〇二三年三月十七日 1.召开时间：2023 年 3 月 28 日（星期二）15:00-17:00 2.出席人员：公司董事、总经理林志成先生，独立董事邓传远先生，董事会秘书唐 金银女士，财务总监吴卓艺女士。 3.接入方式：投资者可登陆深圳证券交易所"互动易"平台（http://irm.cninfo.com.c n） 进入"云访谈"栏目参与公司 2022 年度网络业绩说明会。 二、征集问题事项 为做好中小投资者保护工作，增进投资者对公司的了解和认同，提升交流针对性 ...